UKKW Expert panel: Clinical Data
Overview
Dr Chee Kay Cheung reviews clinical trial data on sparsentan in IgA nephropathy, focusing on its dual mechanism, impact on proteinuria and kidney function, and its role alongside current therapies, supported by findings from the PROTECT study and real-world evidence.
Download the certificate here once you have completed this webinar
Prescribing information and adverse event reporting information:
Filspari®▼(sparsentan): 200 mg , 400 mg
UK-SPT-2500151 (V2.0) | September 2025
Adverse events should be reported. Reporting forms and information for the United Kingdom can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Vifor Fresenius Medical Care Renal Pharma, care of Vifor Pharma Ltd.
Tel: +44 1276 853633. E-mail: MedicalInfo_UK@viforpharma.com.
